Cavallino Chiara, Facchini Manuela, Veia Alessia, Bacchni Sara, Rosso Roberta, Rognoni Andrea, Rametta Francesco, Lupi Alessandro, Bongo Angelo S
Catheterization Laboratory, Maggiore della Carità Hospital, Corso Mazzini 18, 28100 Novara, Italy.
Cardiovasc Hematol Agents Med Chem. 2015;13(1):14-20. doi: 10.2174/1871525713666141219112841.
Chronic angina represents a condition that impairs quality of life and is associated with decreased life expectancy in the industrialized countries. Current therapies that reduce angina frequency include old drugs such as nitrates, β -blockers and calcium antagonists. Several new investigational drugs are being tested for the treatment of chronic angina. This review will focus on ranolazine, a drug approved by the US Food and Drug Administration (FDA) in 2006 for patients with chronic angina who continue to be symptomatic despite optimized therapies. The main molecular mechanism underlying ranolazine-mediated beneficial effects has been identified as inhibition of the late Na+ current during the action potential, which potentially improves oxygen consumption, diastolic dysfunction and coronary blood flow. The aim of this review is to update the evidence for ranolazine treatment in chronic angina and discuss its therapeutic perspectives based on the most recent clinical and experimental studies.
慢性心绞痛是一种会降低生活质量的疾病，在工业化国家中，它与预期寿命缩短有关。目前用于减少心绞痛发作频率的治疗方法包括硝酸盐、β受体阻滞剂和钙拮抗剂等传统药物。有几种新型研究性药物正在进行慢性心绞痛治疗的试验。本综述将聚焦于雷诺嗪，这是一种于2006年获美国食品药品监督管理局（FDA）批准的药物，用于治疗尽管接受了优化治疗仍有症状的慢性心绞痛患者。雷诺嗪产生有益作用的主要分子机制已被确定为抑制动作电位期间的晚钠电流，这可能会改善氧消耗、舒张功能障碍和冠状动脉血流。本综述的目的是更新雷诺嗪治疗慢性心绞痛的证据，并根据最新的临床和实验研究讨论其治疗前景。
